Last updated: September 8, 2026
Vutrisiran sodium, marketed by Alnylam Pharmaceuticals as Amvuttra, is one of the fastest-growing transthyretin amyloidosis therapies. Its commercial position strengthened materially after the FDA approved it for transthyretin-mediated amyloid cardiomyopathy in March 2025. The drug competes with Pfizer’s tafamidis, BridgeBio’s acoramidis, Ionis and AstraZeneca’s eplontersen, and Alnylam’s own patisiran.
Amvuttra’s market trajectory depends on four factors: expansion from hereditary ATTR polyneuropathy into cardiomyopathy, conversion from intravenous or more frequent therapies to quarterly subcutaneous dosing, reimbursement access, and the durability of Alnylam’s patent and orphan-drug protection.
What is vutrisiran sodium and how is Amvuttra used?
Vutrisiran is a chemically modified small interfering RNA, or siRNA, that reduces production of transthyretin, the protein responsible for hereditary and wild-type ATTR amyloidosis. It uses Alnylam’s GalNAc conjugate delivery system to target hepatocytes.
The FDA-approved product is Amvuttra injection, administered subcutaneously at a dose of 25 mg once every three months. The product is indicated for:
- Polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, or ATTRv-PN.
- Cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis, following the March 2025 label expansion.
The quarterly dosing schedule differentiates Amvuttra from patisiran, which requires intravenous administration every three weeks, and from daily oral tafamidis.
What clinical evidence supports vutrisiran?
The HELIOS-A study supported approval in ATTRv-PN. The study showed improvement or stabilization in modified Neurologic Impairment Score plus seven compared with placebo historical control and benefits across neuropathy, quality-of-life and nutritional measures (Adams et al., 2021).
The HELIOS-B study evaluated vutrisiran in ATTR-CM. The study reported reductions in the composite of all-cause mortality and recurrent cardiovascular events, together with favorable effects on functional and quality-of-life measures. The data supported the FDA’s 2025 cardiomyopathy approval (Alnylam Pharmaceuticals, 2024).
What is the FDA regulatory status of vutrisiran?
| Milestone |
Date |
Regulatory significance |
| FDA approval for ATTRv-PN |
July 2021 |
Initial U.S. approval |
| European Commission approval |
September 2022 |
Regional expansion |
| HELIOS-B positive topline results |
2024 |
Supported cardiomyopathy expansion |
| FDA approval for ATTR-CM |
March 2025 |
Expanded eligible population |
| Current dosage |
Ongoing |
25 mg subcutaneous injection every three months |
The 2025 cardiomyopathy approval substantially enlarges the addressable population because wild-type ATTR-CM is more prevalent than hereditary ATTR-PN. The approval also places Amvuttra directly against tafamidis and acoramidis in a high-value cardiology market.
How large is the market for vutrisiran?
ATTR is divided commercially into hereditary disease and wild-type disease.
| Market segment |
Primary patient profile |
Commercial relevance for Amvuttra |
| ATTRv-PN |
Patients with hereditary TTR mutations and peripheral neuropathy |
Established launch market |
| Hereditary ATTR-CM |
Mutation-positive patients with cardiac involvement |
Expansion opportunity |
| Wild-type ATTR-CM |
Predominantly older male patients with cardiomyopathy |
Largest commercial opportunity |
| Mixed phenotype |
Patients with both cardiac and neurologic disease |
Supports broad prescribing |
The cardiomyopathy market is considerably larger than the hereditary polyneuropathy market. Diagnosis remains a constraint. ATTR-CM is frequently underdiagnosed because its symptoms overlap with heart failure with preserved ejection fraction, hypertrophic cardiomyopathy and age-related cardiac disease.
Commercial growth will depend on disease identification, amyloid referral centers, genetic testing, nuclear scintigraphy, cardiology adoption and payer policies. Alnylam has an advantage in ATTR disease education because it already markets both Amvuttra and Onpattro.
How does vutrisiran compare with tafamidis?
| Factor |
Vutrisiran |
Tafamidis |
| Developer |
Alnylam |
Pfizer |
| Mechanism |
TTR production reduction |
TTR stabilization |
| Administration |
Subcutaneous every three months |
Daily oral capsule |
| ATTRv-PN |
Approved |
Approved in selected regions and indications |
| ATTR-CM |
FDA-approved in 2025 |
Established standard of care |
| Generic exposure |
Low near term |
Low near term |
| Main commercial advantage |
Broad TTR suppression and infrequent dosing |
Oral administration and long commercial history |
| Main commercial risk |
Newer cardiomyopathy market position |
Competition from gene-silencing therapies |
Tafamidis has a major incumbent advantage, substantial physician familiarity and a large clinical evidence base. Vutrisiran has a dosing and mechanism advantage, but payer step edits or requirements to use tafamidis first could restrict uptake.
What are the financial results and revenue drivers for Amvuttra?
Amvuttra has become a central growth product for Alnylam. The company has reported strong year-over-year growth in product sales as it expanded from ATTRv-PN into ATTR-CM and gained use in additional international markets.
Alnylam’s key financial drivers are:
- New ATTR-CM prescriptions after the 2025 FDA approval.
- Conversion from Onpattro to Amvuttra within the company’s TTR franchise.
- U.S. reimbursement and commercial formulary placement.
- European and Japanese uptake.
- Continued use in hereditary disease and mixed cardiac-neurologic presentations.
- Quarterly dosing, which can improve persistence and reduce administration burden.
The principal economic trade-off is a shift from legacy product revenue to a newer product rather than entirely incremental revenue. Amvuttra can expand the franchise, but some sales may represent conversion from Onpattro.
What is the expected financial trajectory?
The likely trajectory has three stages:
| Period |
Financial pattern |
Main catalyst |
| 2021-2023 |
Rapid launch growth from a small base |
ATTRv-PN adoption and conversion from Onpattro |
| 2024-2026 |
Accelerating revenue expansion |
HELIOS-B data and ATTR-CM approval |
| 2027 onward |
Larger but more competitive revenue base |
Market penetration, pricing and competitor launches |
The 2025 cardiomyopathy label expansion is the most important near-term revenue catalyst. It opens the market to patients who may otherwise receive tafamidis or acoramidis. Revenue growth will be strongest if Amvuttra becomes a first-line therapy in newly diagnosed ATTR-CM.
Margin performance should remain attractive because siRNA manufacturing is more complex than conventional small-molecule production but does not require the recurring infusion infrastructure associated with some biologics. Selling costs may increase as Alnylam expands cardiology promotion and diagnostic activity.
What patents protect vutrisiran sodium?
Amvuttra is protected by a combination of composition-of-matter, conjugate, siRNA sequence, formulation, manufacturing and use patents. The commercial protection is broader than a single active-ingredient patent because the product depends on a specific liver-targeted RNAi architecture.
Publicly identified U.S. patent protection includes patent families covering vutrisiran-related RNAi conjugates and formulations. U.S. Patent No. 11,612,609 is among the patents associated with Alnylam’s RNAi product platform and has a listed term extending into the late 2030s, subject to terminal disclaimers, patent-term adjustment and regulatory patent-term extension.
| Protection category |
Relevance |
| siRNA sequence patents |
Protect the target-specific RNA sequence |
| GalNAc conjugate patents |
Protect hepatocyte delivery technology |
| Double-stranded RNA architecture |
Protect chemical and structural design |
| Pharmaceutical composition patents |
Protect injectable formulations |
| Method-of-use patents |
Protect treatment of ATTRv-PN and ATTR-CM |
| Manufacturing patents |
Raise the complexity of non-infringing production |
What is the Orange Book status of Amvuttra?
Amvuttra is an FDA-approved prescription product subject to Orange Book patent listing. The listed patent position can change through FDA updates, patent expiration, patent-term adjustment and litigation outcomes. The principal practical issue for generic applicants is whether a proposed product would infringe claims covering the active siRNA, conjugate structure, formulation or method of treating ATTR.
The product’s orphan-drug exclusivity is commercially important. The original ATTRv-PN approval received seven years of orphan exclusivity from the date of approval, subject to the scope of the orphan indication. The 2025 ATTR-CM approval may create additional regulatory protection if the indication qualifies under FDA orphan-drug rules, but orphan exclusivity does not prevent all forms of competition outside the protected indication.
When does vutrisiran lose exclusivity?
The principal exclusivity dates are:
- New chemical entity exclusivity: expected to run for five years from the 2021 approval, absent an applicable extension.
- ATTRv-PN orphan exclusivity: generally calculated from the July 2021 approval date and expected to extend into 2028.
- Patent protection: key platform and product patents may extend into the late 2030s, depending on the specific patent family.
- ATTR-CM regulatory protection: depends on the final FDA exclusivity records and the scope of the new indication.
Patent expiry is more important than NCE exclusivity for generic entry. An ANDA applicant could challenge listed patents through Paragraph IV certification before all patent terms expire.
Which companies are challenging or competing with Amvuttra?
No broad generic competition is expected in the near term. The main threats are branded competitors and potential future RNAi products.
| Company |
Product |
Competitive position |
| Pfizer |
Vyndaqel/Vyndamax, tafamidis |
Established ATTR-CM leader |
| BridgeBio |
Attruby, acoramidis |
Oral TTR stabilizer approved for ATTR-CM |
| Ionis/AstraZeneca |
Wainua, eplontersen |
Antisense therapy for ATTRv-PN |
| Alnylam |
Onpattro, patisiran |
Same-company predecessor in RNAi |
| Ionis |
Next-generation TTR agents |
Potential future competition |
| Academic and biotech developers |
Gene editing and gene silencing programs |
Longer-term platform risk |
Biosimilar risk is not the principal issue because vutrisiran is a synthetic oligonucleotide rather than a conventional protein biologic. The more relevant risk is follow-on competition from other nucleic-acid medicines, including improved dosing, broader phenotype coverage or lower-cost manufacturing.
What Paragraph IV and generic launch risks exist?
A future generic or follow-on applicant could use an ANDA, a 505(b)(2) application or another abbreviated pathway depending on the product’s formulation and regulatory strategy.
The main legal risks include:
- Infringement of composition and sequence claims.
- Infringement of GalNAc conjugate claims.
- Method-of-use claims covering ATTR-CM or ATTRv-PN.
- Formulation claims covering the injectable product.
- Regulatory exclusivity blocking approval even if a patent challenge succeeds.
- Manufacturing-process claims that complicate commercial-scale production.
A Paragraph IV challenge could trigger patent litigation under the Hatch-Waxman framework. The commercial launch date would depend on litigation timing, claim construction, settlement terms and any 30-month stay.
What patent litigation or settlement agreements affect vutrisiran?
The central litigation risk is likely to arise from Alnylam’s broad RNAi platform portfolio rather than from a single narrow product patent. Alnylam has historically used patent litigation to protect siRNA chemistry, conjugate technology and commercial products.
No major public settlement involving an authorized generic of Amvuttra has established an early generic-entry date. Any future settlement would need close review for:
- Authorized-generic provisions.
- Entry dates tied to patent expiry.
- Royalty terms.
- Restrictions on cardiomyopathy or polyneuropathy indications.
- Manufacturing licenses.
- Antitrust scrutiny under FTC policy.
What manufacturing and intellectual-property barriers protect Amvuttra?
Manufacturing is a meaningful barrier to entry. Vutrisiran requires:
- Controlled synthesis of chemically modified oligonucleotides.
- Conjugation to a hepatocyte-targeting ligand.
- Purification of a structurally defined siRNA product.
- Analytical characterization of impurities and duplex integrity.
- Sterile injectable formulation and fill-finish capacity.
A competitor may be able to design a non-infringing sequence but still face development, comparability and manufacturing challenges. The FDA may require substantial analytical and clinical evidence for a follow-on product because small changes in oligonucleotide chemistry or conjugation can affect distribution, potency and safety.
What licensing deals and commercial partnerships involve vutrisiran?
Alnylam retains the principal commercial rights to Amvuttra in major markets. The company’s broader commercial model includes regional partnerships, distributor arrangements and collaborations related to RNAi technology.
The most important strategic relationship is Alnylam’s long-standing development and commercialization collaboration with Roche for certain RNAi programs, although Amvuttra itself remains an Alnylam commercial product. Vutrisiran’s value is therefore tied to Alnylam’s internal commercial infrastructure and its broader RNAi platform rather than to a single external licensee.
What is the generic launch scenario for vutrisiran?
The most probable launch sequence is:
- Continued branded competition through 2027.
- Greater ATTR-CM adoption after the 2025 approval.
- Potential patent challenges before late-2030s patent expiry.
- Follow-on nucleic-acid competition before a conventional generic becomes commercially viable.
- Price pressure emerging first through payer negotiation and competing branded therapies.
An immediate low-cost generic launch is unlikely while the key patent and orphan-protection framework remains active. The more credible near-term risk is market-share erosion from tafamidis, acoramidis and next-generation antisense or RNAi therapies.
How strong is the vutrisiran patent estate?
The estate is strong in commercial terms because protection is layered across product design, delivery technology, formulation, manufacturing and therapeutic use. Its main weaknesses are the possibility that a court narrows broad platform claims, that a competitor designs around a sequence or conjugate claim, or that competing therapies avoid direct infringement through a different mechanism.
The strongest assets are likely the claims that tie the specific vutrisiran structure to the commercial product. Platform patents can be powerful but are more vulnerable to validity and claim-scope disputes.
Key Takeaways
- Vutrisiran sodium is marketed as Amvuttra by Alnylam Pharmaceuticals.
- The March 2025 FDA approval for ATTR-CM materially expanded the addressable market.
- The principal commercial competitor is Pfizer’s tafamidis, with acoramidis and eplontersen increasing pressure.
- Quarterly subcutaneous dosing is a major differentiation from tafamidis and patisiran.
- Amvuttra’s revenue trajectory is positioned for acceleration through cardiomyopathy uptake and conversion from Onpattro.
- Generic competition is unlikely to be the main near-term threat.
- Patent protection extends across siRNA structure, GalNAc delivery, formulation, manufacturing and use.
- The most important commercial risk is branded competition in ATTR-CM, not biosimilar substitution.
- Manufacturing complexity and analytical requirements raise barriers to follow-on entry.
- Alnylam’s long-term value depends on converting a growing ATTR market into durable Amvuttra share without excessive price discounting.
FAQs
Is vutrisiran the same as patisiran?
No. Both are Alnylam siRNA therapies that reduce transthyretin production, but vutrisiran is administered subcutaneously every three months, while patisiran requires intravenous administration every three weeks.
Is Amvuttra approved for wild-type ATTR cardiomyopathy?
Yes. The FDA approved vutrisiran for transthyretin-mediated cardiomyopathy, including wild-type and hereditary forms, in March 2025.
Does Amvuttra have biosimilar competition?
No conventional biosimilar competition is established. Vutrisiran is a synthetic oligonucleotide, so future competition is more likely to come from follow-on RNA medicines than from traditional biosimilars.
What is the biggest commercial threat to Amvuttra?
The biggest threat is branded competition in ATTR-CM, especially tafamidis and acoramidis, followed by future antisense and RNAi therapies with longer dosing intervals or lower cost.
Can a generic company challenge Amvuttra patents?
Yes. A future ANDA applicant could file a Paragraph IV certification against listed patents. Any resulting litigation, regulatory exclusivity and settlement terms would determine the earliest commercial entry date.
References
-
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coats, C. J., Berk, J. L., et al. (2021). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493-504.
-
Alnylam Pharmaceuticals, Inc. (2024). HELIOS-B phase 3 study of vutrisiran in ATTR amyloidosis with cardiomyopathy: Topline results and investor materials. Cambridge, MA.
-
Alnylam Pharmaceuticals, Inc. (2025). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2021). FDA approves first-of-its-kind drug for hereditary transthyretin-mediated amyloidosis. Silver Spring, MD.
-
U.S. Food and Drug Administration. (2025). Amvuttra prescribing information. Silver Spring, MD.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD.
-
U.S. Patent and Trademark Office. (2023). U.S. Patent No. 11,612,609. Washington, DC.
